// App-Quantinova.ai

e19018 : Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO-4538-15): An interim analysis.

Researchers

Presenter

  • Kiyohiko Hatake

Principal Investigators

  • Tomohiro Kinoshita

  • Noriko Fukuhara

  • Ilseung Choi

  • Masafumi Taniwaki

  • Kiyoshi Ando

  • Dai Maruyama

  • Yasuhito Terui

  • Yusuke Higuchi

  • Yasushi Onishi

  • Yasunobu Abe

  • Tsutomu Kobayashi

  • Yukari Shirasugi

  • Kensei Tobinai

Medical Centers

  • Department of Hematology and Oncology, Cancer Institute Hospital, Japanese Foundation For Cancer Research, Tokyo, Japan

  • Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan

  • Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan

  • Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

  • Division of Hematology and Oncology, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan

  • Department of Obstetrics and Gynecology, Tokai Univeresity Hospital, Kanagawa, Japan

  • Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Adcetris

  • Nivolumab

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved